https://www.globenewswire.com/news-release/2024/07/30/2920974/0/en/Yamo-Pharmaceuticals-Announces-Positive-Topline-Results-from-Phase-2-Study-of-L1-79-for-the-Treatment-of-the-Core-Symptoms-of-Autism.html
